Plain-English translation of NCT07208136 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new drug called in patients with advanced cancers that have specific genetic defects—either microsatellite instability or mismatch repair deficiency. The trial will examine whether the medication is safe, how your body processes it, and whether it helps shrink or slow down tumors. This is the first time this medication is being tested in humans.
Certain advanced cancers have genetic 'glitches' in their DNA repair systems, which can make them harder to treat with standard therapies. Researchers believe this new medication may be able to target and attack cancers with these specific genetic changes.
You likely qualify if…
You likely don't qualify if…
You will take tablets of the medication by mouth at doses that researchers will gradually increase as they learn more about safety. You'll visit the clinic regularly for blood tests, imaging scans, and physical exams to monitor how well the medication is working and check for side effects. The trial involves multiple visits over several months, with the exact schedule depending on which dose group you're placed in.
AI-generated summary from trial data · Sep 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Jemincare
Enrollment target
~102 participants
Started
October 2025
Primary completion
December 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lu Chen
Peking University Cancer Hospital & Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.